相关实验视频
Updated: Aug 13, 2026

Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
免疫逃生相关基因在肺腺癌的预后价值
Hao Ran Jia1, Wen Chao Li1, Lin Wu1
1Department of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
这项研究确定了肺腺癌 (LUAD) 中关键的免疫逃生相关基因 (IERG). 包括CEP55和AHSA1在内的四基因模型可以预测LUAD患者的预后,并可能提供新的治疗点.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
背景情况:
- 肺腺癌 (LUAD) 是一种流行癌症类型.
- 免疫逃逸显著促进LUAD的进展,并阻碍了免疫治疗的有效性.
- 识别与免疫逃生相关的基因 (IERG) 对于改善LUAD患者的治疗结果至关重要.
研究的目的:
- 在LUAD.中识别异常表达的免疫逃生相关基因 (IERGs).
- 根据IERG开发一个基于LUAD的预后模型.
- 探索LUAD治疗的潜在治疗点.
主要方法:
- 利用癌症基因组图谱 (TCGA) 数据库用于LUAD RNA数据.
- 采用权重基因联合表达网络分析 (WGCNA) 来识别关键基因.
- 应用LASSO和考克斯回归来构建预后风险模型.
- 使用基因表达综合 (GEO) 数据集验证了模型.
主要成果:
- 确定了与免疫和亡途径相关的20个差异表达的IERG.
- 开发并验证了LUAD的四基因预后模型.
- 发现,与正常组织相比,AHSA1和CEP55在LUAD组织中表达高.
结论:
- 一个基于IERG的模型有效地预测了LUAD的预后.
- AHSA1和CEP55是LUAD的潜在预后和治疗标.
- 针对AHSA1和CEP55可能为LUAD提供一种新的治疗策略.
更多相关视频
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
相关概念视频
Cancer
Cancer Prevention
Some...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Cancer Survival Analysis